Panagora Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $643K | Sell |
2,834
-3,239
| -53% | -$577K | ﹤0.01% | 834 |
|
|
2026
Q1 | $1.05M | Hold |
6,073
| – | – | ﹤0.01% | 704 |
|
|
2025
Q4 | $1.21M | Buy |
+6,073
| New | +$1.1M | ﹤0.01% | 665 |
|
|
2024
Q4 | – | Sell |
-2,554
| Closed | -$503K | – | 1164 |
|
|
2024
Q3 | $503K | Hold |
2,554
| – | – | ﹤0.01% | 928 |
|
|
2024
Q2 | $528K | Sell |
2,554
-1,806
| -41% | -$409K | ﹤0.01% | 898 |
|
|
2024
Q1 | $1.18M | Hold |
4,360
| – | – | 0.01% | 737 |
|
|
2023
Q4 | $1.03M | Hold |
4,360
| – | – | 0.01% | 804 |
|
|
2023
Q3 | $854K | Hold |
4,360
| – | – | 0.01% | 825 |
|
|
2023
Q2 | $917K | Hold |
4,360
| – | – | 0.01% | 815 |
|
|
2023
Q1 | $880K | Sell |
4,360
-2,532
| -37% | -$574K | 0.01% | 886 |
|
|
2022
Q4 | $1.5M | Buy |
6,892
+4,170
| +153% | +$911K | 0.01% | 724 |
|
|
2022
Q3 | $536K | Hold |
2,722
| – | – | ﹤0.01% | 1114 |
|
|
2022
Q2 | $582K | Hold |
2,722
| – | – | ﹤0.01% | 1106 |
|
|
2022
Q1 | $773K | Buy |
2,722
+1,913
| +236% | +$590K | ﹤0.01% | 1049 |
|
|
2021
Q4 | $305K | Sell |
809
-1,153
| -59% | -$448K | ﹤0.01% | 1372 |
|
|
2021
Q3 | $810K | Sell |
1,962
-111
| -5% | -$46.1K | ﹤0.01% | 1062 |
|
|
2021
Q2 | $767K | Sell |
2,073
-39
| -2% | -$13K | ﹤0.01% | 1135 |
|
|
2021
Q1 | $612K | Sell |
2,112
-27
| -1% | -$7.5K | ﹤0.01% | 1238 |
|
|
2020
Q4 | $534K | Buy |
2,139
+66
| +3% | +$15.7K | ﹤0.01% | 1197 |
|
|
2020
Q3 | $469K | Sell |
2,073
-1
| -0% | -$208 | ﹤0.01% | 1187 |
|
|
2020
Q2 | $362K | Sell |
2,074
-1
| -0% | -$160 | ﹤0.01% | 1321 |
|
|
2020
Q1 | $262K | Sell |
2,075
-135
| -6% | -$20.2K | ﹤0.01% | 1372 |
|
|
2019
Q4 | $338K | Buy |
2,210
+135
| +7% | +$18.7K | ﹤0.01% | 1431 |
|
|
2019
Q3 | $275K | Sell |
2,075
-40,910
| -95% | -$5.49M | ﹤0.01% | 1519 |
|
|
2019
Q2 | $6.1M | Sell |
42,985
-64,130
| -60% | -$8.7M | 0.03% | 444 |
|
|
2019
Q1 | $15.6M | Sell |
107,115
-3,122
| -3% | -$410K | 0.07% | 267 |
|
|
2018
Q4 | $12.5M | Sell |
110,237
-83,963
| -43% | -$10.5M | 0.06% | 270 |
|
|
2018
Q3 | $26.1M | Sell |
194,200
-9,079
| -4% | -$1.12M | 0.1% | 202 |
|
|
2018
Q2 | $22.8M | Sell |
203,279
-5,381
| -3% | -$582K | 0.09% | 214 |
|
|
2018
Q1 | $22.3M | Sell |
208,660
-124,908
| -37% | -$13.5M | 0.09% | 207 |
|
|
2017
Q4 | $36.5M | Sell |
333,568
-119,923
| -26% | -$13.1M | 0.14% | 170 |
|
|
2017
Q3 | $49M | Buy |
453,491
+231,667
| +104% | +$23.8M | 0.19% | 123 |
|
|
2017
Q2 | $22.4M | Buy |
221,824
+935
| +0.4% | +$86.1K | 0.09% | 229 |
|
|
2017
Q1 | $19.9M | Sell |
220,889
-67,520
| -23% | -$5.73M | 0.08% | 260 |
|
|
2016
Q4 | $22M | Sell |
288,409
-163,897
| -36% | -$12.4M | 0.1% | 200 |
|
|
2016
Q3 | $37.7M | Buy |
452,306
+48,496
| +12% | +$4.07M | 0.18% | 123 |
|
|
2016
Q2 | $33.3M | Buy |
403,810
+4,342
| +1% | +$358K | 0.17% | 129 |
|
|
2016
Q1 | $30.3M | Buy |
399,468
+26,165
| +7% | +$1.94M | 0.15% | 148 |
|
|
2015
Q4 | $30M | Buy |
373,303
+74,071
| +25% | +$5.34M | 0.15% | 154 |
|
|
2015
Q3 | $19M | Buy |
299,232
+77,645
| +35% | +$5.58M | 0.1% | 218 |
|
|
2015
Q2 | $15.6M | Sell |
221,587
-1,225
| -0.5% | -$90.7K | 0.08% | 271 |
|
|
2015
Q1 | $17.7M | Buy |
222,812
+43,774
| +24% | +$3.23M | 0.09% | 238 |
|
|
2014
Q4 | $11.4M | Sell |
179,038
-525
| -0.3% | -$32.9K | 0.06% | 306 |
|
|
2014
Q3 | $10.7M | Sell |
179,563
-21,872
| -11% | -$1.25M | 0.05% | 325 |
|
|
2014
Q2 | $10.8M | Sell |
201,435
-9,945
| -5% | -$546K | 0.05% | 331 |
|
|
2014
Q1 | $12.8M | Buy |
211,380
+157,353
| +291% | +$9.17M | 0.06% | 297 |
|
|
2013
Q4 | $2.87M | Buy |
54,027
+34,928
| +183% | +$1.75M | 0.01% | 716 |
|
|
2013
Q3 | $884K | Hold |
19,099
| – | – | ﹤0.01% | 1152 |
|
|
2013
Q2 | $784K | Buy |
+19,099
| New | +$818K | ﹤0.01% | 1156 |
|
Other funds holding CRL
AI
Panagora Asset Management's CRL Position: Q2 2026 in Review
Panagora Asset Management reduced its Charles River Laboratories (CRL) stake by 53% in Q2 2026, selling an estimated $577K and leaving 2,834 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #834.
Panagora Asset Management first reported a position in CRL in Q2 2013 and has held it in 49 quarters since. The position peaked at $49M in Q3 2017. 564 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Panagora Asset Management held 2,834 shares of Charles River Laboratories worth $643K as of Q2 2026.
- Panagora Asset Management sold 3,239 Charles River Laboratories shares in Q2 2026, an estimated $577K.
- Charles River Laboratories made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #834 holding.
- Panagora Asset Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 49 quarters since.
- Panagora Asset Management's Charles River Laboratories position peaked at $49M in Q3 2017.
- 564 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.